Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study.

ABSTRACT:

Background

Anti-TNF antibodies were the first biologic treatment option for patients with inflammatory bowel diseases.

Aims

To assess length of treatment persistence of first anti-TNF therapy and influencing factors used in the standard care of patients with inflammatory bowel diseases.

Methods

Single-centre, retrospective study from a register including patients who received anti-TNF therapy in the last 20 years at the study centre. Kaplan-Meier analysis with log-rank test was used to describe treatment persistence. With multivariable Cox regression analysis, risk factors for treatment failure were investigated.

Results

Five hundred thirty-eight patients (CD, Crohn's disease: 367, UC, ulcerative colitis: 147, inflammatory bowel disease unclassified: 24) with a

SUBMITTER: Blesl A 

PROVIDER: S-EPMC8453765 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature